Physician profile
Mark A Goldstein
NPI 1679568885
$23,333.33
in general payments reported to CMS, 2019-2025
36 companies · $3,409 in 2025
The $3,409 reported for 2025 was more than what 80% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,838 · 2020: $1,610 · 2021: $2,580 · 2022: $3,930 · 2023: $3,966 · 2024: $4,001 · 2025: $3,409.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,375.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $6,296.07 | 2019-2025 | |
| Amgen INC. | $3,300.71 | 2019-2025 | Enbrel, Tavneos, Evenity |
| Pfizer INC. | $2,113.89 | 2019-2025 | |
| Janssen Biotech, INC. | $1,738.07 | 2019-2025 | Tremfya, Simponi Aria |
| Astrazeneca Pharmaceuticals LP | $1,198.70 | 2021-2025 | Saphnelo |
| Ucb, INC. | $1,123.25 | 2019-2025 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $959.12 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $846.94 | 2019-2025 | Orencia |
| Lilly USA, LLC | $702.96 | 2019-2025 | Taltz |
| Aurinia Pharma U.S., INC. | $674.39 | 2021-2025 | Lupkynis |
| Glaxosmithkline, LLC. | $585.66 | 2019-2025 | Benlysta, Nucala |
| Horizon Therapeutics Plc | $548.50 | 2019-2022 | |
| Genentech USA, INC. | $437.00 | 2019-2025 | Actemra, Rituxan, Gazyva |
| Radius Health, INC. | $386.49 | 2021-2025 | Tymlos, Binosto |
| Genzyme Corporation | $333.02 | 2022-2025 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fidia Pharma USA INC. | $266.00 | 2019-2025 | Hymovis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $245.62 | 2023-2024 | Cyltezo, Spevigo |
| Regeneron Healthcare Solutions, INC. | $221.79 | 2019 | |
| Mallinckrodt Enterprises LLC | $211.58 | 2019 | |
| Mallinckrodt Hospital Products INC. | $194.26 | 2020-2024 | Acthar |
| Hikma Pharmaceuticals USA | $177.41 | 2019-2022 | |
| Celgene Corporation | $144.11 | 2019 | |
| Fresenius Kabi USA, LLC | $108.08 | 2023-2025 | Idacio |
| Pacira Therapeutics, INC. | $94.49 | 2019 | |
| Antares Pharma, INC. | $78.62 | 2019-2021 | |
| Ani Pharmaceuticals, INC. | $73.23 | 2024-2025 | Purified Cortrophin Gel |
| Sobi, INC | $65.91 | 2025 | |
| Merck Sharp & Dohme LLC | $55.92 | 2025 | |
| Sebela Pharmaceuticals INC. | $41.55 | 2019 | |
| Bioventus LLC | $22.01 | 2022 | |
| Scilex Pharmaceuticals INC. | $17.31 | 2024 | |
| Tonix Medicines, INC. | $16.27 | 2025 | Tonmya |
| Ferring Pharmaceuticals INC. | $15.99 | 2022 | |
| Medexus Pharma, INC. | $13.07 | 2019 | |
| Daiichi Sankyo INC. | $13.02 | 2019 | |
| Sanofi-Aventis U.S. LLC | $12.32 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Goldstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.